Exchange: OTC·Updated 05:01 PM EDT

RHHBYRoche Holdings AG ADR

$51.76
$0.41
(0.79%)
Today
Closed $51.76
$0.00
(0.00%)
After Hours
EarningsJul 23
Mkt Cap$285.27B
Vol1.5M
News
all
press releases
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY
SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.
Stocktwits
News Placeholder
More News
News Placeholder
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Zacks
News Placeholder
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
Zacks
News Placeholder
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Zacks
News Placeholder
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Zacks
News Placeholder
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
Zacks
News Placeholder
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
Zacks
News Placeholder
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
Zacks
News Placeholder
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
Zacks
News Placeholder
Novartis Reports Positive Data for Neuromuscular Disorder Drug
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Zacks
<
1
2
...
>